Atlas Trials

Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors

Clinical trial NCT06031480 · UNKNOWN

Trial details

NCT number
NCT06031480
Sponsor
Shanghai Zhongshan Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2023-10-31
Primary completion
2025-10-31
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.